The DOI matches its Crossref record; 101 of the 104 references it cites were found in a registry or an index.
Overview of Castleman disease
Open accessAbstract
Castleman disease (CD) describes a group of at least 4 disorders that share a spectrum of characteristic histopathological features but have a wide range of etiologies, presentations, treatments, and outcomes. CD includes unicentric CD (UCD) and multicentric CD (MCD), the latter of which is divided into idiopathic MCD (iMCD), human herpes virus-8 (HHV8)-associated MCD (HHV8-MCD), and polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS)-associated MCD (POEMS-MCD). iMCD can be further subclassified into iMCD–thrombocytopenia, ascites, reticulin fibrosis, renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD–not otherwise specified (iMCD-NOS). Advances in diagnosis, classification, pathogenesis, and therapy are substantial since the original description of UCD by Benjamin Castleman in 1954. The advent of effective retroviral therapy and use of rituximab in HHV8-MCD have improved outcomes in HHV8-MCD. Anti–interleukin-6–directed therapies are highly effective in many iMCD patients, but additional therapies are required for refractory cases. Much of the recent progress has been coordinated by the Castleman Disease Collaborative Network (CDCN), and further progress will be made by continued engagement of physicians, scientists, and patients. Progress can also be facilitated by encouraging patients to self-enroll in the CDCN’s ACCELERATE natural history registry (#NCT02817997; www.CDCN.org/ACCELERATE).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with HHV-8–associated multicentric Castleman’s disease are immunocompromised as a result of human immunodeficiency virus infection or a genetic susceptibility, making it difficult to control the HHV-8 infection, which is a common, typically asymptomatic infection in the general population.69”
From Cytokine storm (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.
Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M., Clauvel, J., Raphael, M., Degos, L., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1276.bloodjournal8641276 · Cited by 2,296
POEMS syndrome: definitions and long-term outcome
Dispenzieri, A. A., Kyle, R. A., Lacy, M. Q., Rajkumar, S. V., Therneau, T. M., Larson, D. R., Greipp, P. R., Witzig, T. E., Basu, R., Suárez, G. A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2299 · Cited by 817
Self-citationNishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 781
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Plasma Cell Dyscrasia with Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes
Bardwick, P. A., Zvaifler, N. J., Gill, G. N., NEWMAN, D., Greenway, G. D., & RESNICK, D. L. (1980) · Medicine · doi:10.1097/00005792-198007000-00006 · Cited by 698
Dupin, N., Diss, T. C., Kellam, P., Tulliez, M., Du, M., Sicard, D., Weiss, R. A., Isaacson, P. G., & Boshoff, C. (2000) · Blood · doi:10.1182/blood.v95.4.1406.004k26_1406_1412 · Cited by 648
Fajgenbaum, D., Uldrick, T., Bagg, A., Frank, D. M., Wu, D., Srkalović, G., Simpson, D., Liu, A. Y., Menke, D., Chandrakasan, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-746933 · Cited by 601
Self-citationNakanishi, T., SOBUE, I., TOYOKURA, Y., Nishitani, H., Kuroiwa, Y., Satoyoshi, E., Tsubaki, T., Igata, A., & Ozaki, Y. (1984) · Neurology · doi:10.1212/wnl.34.6.712 · Cited by 552
van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70319-5 · Cited by 454
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males
Bollschweiler, E., Wolfgarten, E., Gutschow, C. A., & H�lscher, A. H. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3 · Cited by 452
Research works printed but not linked: 2
- Flendrig, 1969, Benign giant lymphoma: the clinical signs and symptoms and the morphological aspects.y, Folia Med Neerl, 12, 119
- Takai, 2010, Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly [in Japanese], Rinsho Ketsueki, 51, 320
Cited by
Sorted by citations
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Self-citationCytokine Storm—Definition, Causes, and Implications
Jarczak, D., & Nierhaus, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911740 · Cited by 336
Carbone, A., Borok, M. Z., Damania, B., Gloghini, A., Polizzotto, M. N., Jayanthan, R., Fajgenbaum, D. C., & Bower, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00317-7 · Cited by 214
Self-citationWeathering the COVID-19 storm: Lessons from hematologic cytokine syndromes
England, J. T., Abdulla, A., Biggs, C. M., Lee, A. Y. Y., Hay, K. A., Hoiland, R. L., Wellington, C. L., Sekhon, M. S., Jamal, S., Shojania, K., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100707 · Cited by 179
Nishimura, Y., Fajgenbaum, D. C., Pierson, S. K., Iwaki, N., Nishikori, A., Kawano, M., Nakamura, N., Izutsu, K., Takeuchi, K., Nishimura, M. F., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26292 · Cited by 138
Self-citation
Metadata
- Authors
- Dispenzieri, A., & Fajgenbaum, D. C.
- Affiliations
- Mayo Clinic (US)
- University of Pennsylvania (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-04-16
- Volume
- 135
- Issue
- 16
- Pages
- 1353-1364
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3006713791
- Cited by
- 487
- References
- 104
- Citations by year
- 2026: 69 · 2025: 90 · 2024: 90 · 2023: 81 · 2022: 91 · 2021: 52 · 2020: 13
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- National Institutes of Health (2r01hl141408-06)
- National Heart, Lung, and Blood Institute (R01-HL141408)
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphadenopathy Diagnosis and Analysis
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- Castleman disease, unicentric Castleman disease, multicentric Castleman disease, idiopathic multicentric Castleman disease, POEMS syndrome, rituximab, disease classification, pathogenesis
- MeSH terms
- Rituximab, Interleukin-6 Inhibitors, Animals, Castleman Disease, Herpesviridae Infections, Humans, Immunologic Factors, Herpesvirus 8, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
